A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Precision Genetics Launches a New Diagnostic to Detect COVID-19 and the Flu

November 10, 2020

Precision Genetics, a leader in the molecular laboratory and technology industries, announces today the launch of a new diagnostic test that simultaneously detects SARS-CoV-2 and Influenza A/B strains in upper respiratory tract specimens.

Precision Genetics notes the test is available to health systems, providers, employers, and academic institutions alike.

Precision Genetics’ capabilities are essential for accurately detecting patients with COVID-19 and/or the flu. “By utilizing our high-complexity laboratory and testing methods, we can quickly and accurately distinguish between these viral infections,” said Nate Wilbourne, founder and CEO of Precision Genetics. “Our goal as a molecular laboratory is to ensure the highest levels of quality and efficiency to our clinical partners.”

The addition of this combination test comes just in time for the flu season.  “Most current testing looks only for COVID-19. As influenza infection rates rise, testing individuals only for Covid-19 is insufficient to distinguish between various viral illnesses of the upper respiratory tract,” said John Wrangle, M.D, Chief Medical Officer of Precision Genetics.  “Knowing which virus a patient is infected with may help treating physicians, health professionals and health departments decide on the best course of treatment, surveillance and contact tracing.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.
The company announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits, the antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of tumor heterogeneity and disease progression at various stages.
Proteintech advises the new building houses research and development, production, logistics and administration in an area more than three times larger than its previous space.
In September 2023, Seegene and Springer Nature opened applications to scientists and experts across the global community to conduct research for the 15 designated projects to develop Seegene's syndromic qPCR diagnostics assay reagents for the Open Innovation Program.
Lindus Health has taken learnings from this experience to build a bespoke "All-in-One Metabolic CRO" offering that combines the expertise of a seasoned full service CRO and internal site/PI expertise with a distinctive technology driven approach on its proprietary Citrus™ platform. This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.

By using this website you agree to accept Medical Device News Magazine Privacy Policy